March 10, 2021 -- Sorrento Therapeutics and the Icahn School of Medicine at Mount Sinai have entered into an exclusive license agreement for a collection of antibodies developed at Mount Sinai that have SARS-CoV-2 neutralizing properties.
The agreement is aimed at developing Covishield, a combination of two monoclonal antibodies designed to protect against disease caused by existing and emerging variants of SARS-CoV-2. The therapy has potent activity against a number of variants including the U.K. (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants, according to Sorrento.
Laboratory study of Covishield is expected to support the future research path and regulatory review by the U.S. Food and Drug Administration (FDA).
The license also addresses Sorrento and Mount Sinai pursuing future collaborations in developing humanized monoclonal antibodies for therapeutic applications.
Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
